AgomAb Therapeutics NV’s Lock-Up Period Set To Expire on August 5th (NASDAQ:AGMB)

AgomAb Therapeutics’ (NASDAQ:AGMB) lock-up period is set to expire on Wednesday, August 5th. AgomAb Therapeutics had issued 12,500,000 shares in its public offering on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. After the expiration of AgomAb Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analysts Forecast Growth

AGMB has been the topic of several recent research reports. HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 target price on the stock. B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Stock Up 0.9%

AGMB opened at $12.87 on Friday. AgomAb Therapeutics has a 12 month low of $8.75 and a 12 month high of $17.82. The business’s fifty day moving average is $11.97.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.